Fianlimab + Cemiplimab for Melanoma

This trial explores the effectiveness of combining two drugs, Fianlimab and Cemiplimab, in treating melanoma (a type of skin cancer) before and after surgery. Researchers aim to determine if these drugs can reduce the cancer more effectively. Participants will receive varying doses of the drug combination before surgery and continue treatment afterward. Suitable candidates for this trial have melanoma that can be surgically removed and experience symptoms such as visible skin changes or growths. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to get a clear answer.

A previous study found the combination of Fianlimab and Cemiplimab to be safe for people with melanoma, a type of skin cancer. Research shows that the side effects resemble those of other treatments targeting PD-1, a protein that helps control the immune system. This indicates that patients generally tolerate the treatment well. Some individuals may experience side effects, but these typically align with expectations for this kind of therapy.¹²³⁴⁵

Researchers are excited about Fianlimab and Cemiplimab for melanoma because they combine two powerful immunotherapies that work together to supercharge the immune system. Unlike traditional treatments like surgery, chemotherapy, or radiation, these drugs specifically target and block proteins that normally hold back the immune system's attack on cancer cells. This combination approach has the potential to be more effective in shrinking tumors before surgery and preventing their return, offering new hope for patients with melanoma.

Research has shown that combining Fianlimab and Cemiplimab yields promising results for treating melanoma. In earlier studies, 61.2% of patients experienced tumor reduction or disappearance, with some showing strong and lasting improvements. Another study found that 63% of patients with advanced melanoma responded to this treatment, with some achieving no detectable cancer. In this trial, participants will receive various dosing regimens of Fianlimab and Cemiplimab together, which could effectively treat melanoma.¹²³⁶⁷